Ionis Pharmaceuticals (STU:ISI) Institutional Ownership : 77.71% (As of May. 27, 2024)

View and export this data going back to 1991. Start your Free Trial

What is Ionis Pharmaceuticals Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Ionis Pharmaceuticals's institutional ownership is 77.71%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Ionis Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Ionis Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 84.49%.

Ionis Pharmaceuticals Institutional Ownership Historical Data

The historical data trend for Ionis Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Institutional Ownership Chart

Ionis Pharmaceuticals Historical Data

The historical data trend for Ionis Pharmaceuticals can be seen below:

	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30
Institutional Ownership	81.30	80.78	81.46	78.51	78.83	79.42	78.86	78.69	78.02	77.71

Ionis Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Ionis Pharmaceuticals (STU:ISI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (STU:ISI) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

IONS:USA IONS:Mexico ISI:Germany

Address

2855 Gazelle Court, Carlsbad, CA, USA, 92010

Website

https://www.ionispharma.com

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Ionis Pharmaceuticals (STU:ISI) Headlines

No Headlines